Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04453033 · ClinicalTrials.gov registry record · NA

DB RCT for Specialized Phototherapy in Parkinson's Disease.

A NA study of Parkinson Disease, sponsored by PhotoPharmics.

Active
Registry status
NA
Development phase
350
Enrollment target
1
Study location

NCT04453033 is a NA study of Parkinson Disease that is active but no longer recruiting, run by PhotoPharmics. The registered enrollment target is 350 participants, below the 5,325-participant average among 297 other Parkinson Disease trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04453033, a NA study of Parkinson Disease, is active but no longer recruiting, sponsored by PhotoPharmics.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
350 participants
Enrollment target
1
Study location

Study Summary

This is a pivotal study to determine whether light therapy can improve non-motor and motor function in Parkinson's disease, on top of current best medical treatment.

Conditions Studied

Interventions

  • DEVICE Celeste Specialized Phototherapy Device

Study Locations (1)

New York

  • University of Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 350 participants
Start Date 2024-02-26
Est. Completion 2026-08-30
Phase NA

Sponsor

PhotoPharmics

3 total trials

What the Registry Record Tells You About NCT04453033

The ClinicalTrials.gov registry entry for NCT04453033 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,325-participant average among 297 other Parkinson Disease trials with a reported enrollment target (93% lower). The listed sponsor is PhotoPharmics, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which Celeste Specialized Phototherapy Device is the first listed.

NCT04453033 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT04453033 about?

NCT04453033 is a clinical study titled "DB RCT for Specialized Phototherapy in Parkinson's Disease.". This is a pivotal study to determine whether light therapy can improve non-motor and motor function in Parkinson's disease, on top of current best medical treatment.

What is the current status of trial NCT04453033?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 350 participants. The study started on 2024-02-26. Estimated completion is 2026-08-30.

What conditions does trial NCT04453033 study?

This clinical trial studies the following conditions: Parkinson Disease.

What interventions are being tested in trial NCT04453033?

The interventions under investigation include: Celeste Specialized Phototherapy Device (DEVICE).

Who is sponsoring clinical trial NCT04453033?

This trial is sponsored by PhotoPharmics, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04453033 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.